Ahnal Purohit, PUROHIT NAVIGATION
One of most common mistakes that marketers make during a recession is to focus on cost rather than outcomes.
Ahnal Purohit
PRESIDENT AND CEO | PUROHIT NAVIGATION
One of most common mistakes that marketers make during a recession is to focus on cost rather than outcomes. For example, a comprehensive e-learning program may seem expensive initially, but over time it may deliver a greater return on investment, such as behavior conversion, long term loyalty, and heightened product awareness. Selecting tactics that provide amortized value is more effective than short term, less expensive tactics. Initiating a pharmacoeconomic study, say, can lead to various benefits that can be applied in more than one promotion, such as incorporating pivotal data into sales aids, communicating to managed care groups, and demonstrating value to physicians and patients.
Ahnal Purohit
The FDA's move of "acting in the best interest of consumers" may actually open a Pandora's box. It could allow a rise in advertising from online pharmacies, counterfeit drugs, and alternative therapies—all of which are easily available online and are not as strictly regulated as the pharmaceutical industry.
It will be some time before the FDA issues greater clarification on how to best approach online marketing. In the meantime, marketers do have choices. The first is to redesign their banner ads to include information, such as the generic name and fair balance, in a larger pixel-size format (good luck!). The larger format will incur additional costs for companies, so a closer analysis of the return on investment will need to be made.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
